Stoll, P., Silla, L.M., Cola, C.M., Splitt, B.I., & Moreira, L.B. (2013). Effectiveness of a Protective Environment implementation for cancer patients with chemotherapy-induced neutropenia on fever and mortality incidence. American Journal of Infection Control, 41, 357–359.
To evaluate the significance of a protective environment (PE) on febrile neutropenia and mortality in patients with cancer with chemotherapy-induced neutropenia
The intervention was comprised of engineering and design interventions, incorporating high-efficiency particulate filters, positive air pressure, well-sealed rooms, and infection control routines according to international recommendations for a PE. Outcomes were compared to those of patients admitted prior to the implementation of standard environmental practices.
Fever occurred in 74.7% of episodes of neutropenia in the PE group and in 86.7% in the control group (p = 0.003). Adjusting for length of neutropenia, risk, category, antibacterial prophylaxis, and central venous catheter use, the PE reduced febrile neutropenia (p = 0.009). The PE also decreased overall mortality (p = 0.001) and 30-day mortality (p = 0.002). Gram-negative bacterial infections were more frequent after the intervention (p = 0.18), while gram-positive bacterial infections were similar (p = 0.85). Fungal infections were more frequent in the control group (p = 0.04).
This study shows the advantages of the PE on reducing febrile neutropenia and mortality among patients with cancer and indicates that multiple infection control interventions significantly can diminish hospital-acquired infections.
Although the study does not delineate what they are, an important part of the intervention is infection control routines. These routines include hand hygiene and the routine use of personal protective equipment. Infection control is essential not only to protect nurses, but also to prevent the transmission of infection from one patient to another, particularly when those patients are at higher risk because of chemotherapy-induced neutropenia, and their importance cannot be overstated.
Stokman, M.A., Spijkervet, F.K., Boezen, H.M., Schouten, J.P., Roodenburg, J.L., & deVries, E. G. (2006). Preventive intervention possibilities in radiotherapy and chemotherapy-induced oral mucositis: Results of meta-analysis. Journal of Dental Research, 85, 690–700.
Databases searched were MEDLINE, EMBASE, and CINAHL (1966–2004).
Search keywords were [neoplasms] AND [(mucositis OR stomatitis)] AND [limit to (clinical trial OR randomized-controlled trials)].
Studies were included in the review if they were
The search yielded 109 publications. Of these, five were not aimed at prevention, 13 were nonrandomized, and 29 did not contain data in a comprehensive form. Seventeen articles stood alone in terms of intervention, and 45 articles included meta-analyses. Studies with zero or infinite odds ratios were omitted because variances could not be calculated with accuracy. Sample sizes ranged from 14–502.
Patients with various cancer diagnoses receiving chemotherapy, radiation therapy, or combination chemoradiotherapy.
Of the 27 interventions identified for the prevention of oral mucositis, meta-analysis could be performed on eight. Four interventions showed a preventive effect on the development or severity of oral mucositis: PTA (polymyxin E, tobramycine, and amphotericin B) lozenges or paste, systemic administration of granulocyte macrophage–colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF), oral cooling, and amifostine.
Of 14 studies (each on a different intervention type), nine showed some positive results; however, methodological flaws (e.g., small sample sizes, lack of double-blind or placebo-controlled designs) prevented those studies from demonstrating effectiveness. One study of benzydamine (Epstein et al., 2001) showed an improved ulcer-free rate and decreased incidence of ulcer and erythema.
Palifermin demonstrated positive results for the prevention of mucositis in patients with hematologic malignancies undergoing autologous stem cell transplantation.
Stokman, M.A., Spijkervet, F.K., Burlage, F.R., & Roodenburg, J.L. (2005). Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study. Supportive Care in Cancer, 13, 42–48.
Tooth patches containing 15 mg flurbiprofen or placebo were applied once a day before sleep to the same natural tooth or the upper denture to the buccal side starting one week prior to radiotherapy (RT) until completion of RT. Treatment was discontinued at the first onset of grade 1 ulceration/pseudomembrane formation.
Oral Mucositis Assessment Scale (OMAS) and World Health Organization (WHO) scoring systems were used to evaluate mucositis. Oral pain, pain on swallowing, global assessment of eating function score, and oral washings for viability of mucosal epithelial cells and maturation were used.
Stokman, M. A., Burlage, F.R., & Spijkervet, F.K. (2012). The effect of a calcium phosphate mouth rinse on (chemo) radiation induced oral mucositis in head and neck cancer patients: A prospective study. International Journal of Dental Hygiene, 10(3), 175–180.
To determine the effect of a calcium phosphate (CP) mouth rinse on oral mucositis
Consecutive patients were asked if they were willing to use the CP mouth rinse. Those who were willing were assigned to the CP group, and those who refused served as controls and followed the standard oral care program. Standard care with mouth rinsing with a salt and baking soda solution at least 8 times per day. The CP rinse was used twice per day. All patients received daily oral cleansing with a normal saline pressure spray and fluoride gel applications every other day to the teeth. The study period was 6 weeks. Outcomes were compared between groups and compared with historical controls.
The study was conducted at a single outpatient site in the Netherlands.
Patients were undergoing the active antitumor treatment phase of care.
This was a prospective, non-random comparison study.
No significant differences were found between groups in any of the outcome measures. Patients in the CP group had more severe mucositis scores at most weeks, but the difference was not statistically significant.
CP mouth rinsing had no effect on frequency, severity, or duration of oral mucositis in this group of patients.
This study did not show any benefit in the use of CP mouth rinses for the prevention and management of mucositis in patients receiving radiation therapy for head and neck cancer.
Stockler, M. R., O’Connell, R., Nowak, A. K., Goldstein, D., Turner, J., Wilcken, N. R., Zoloft's Effects on Symptoms and survival Time Trial Group. (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncology, 8, 603–612.
The sertraline intervention required patients to take 50 mg/day of the study drug or a matched placebo for the study period. Patients who developed symptoms of major depression were referred to a psychiatrist coinvestigator at the institution. If there was a definite indication for antidepressants or if patients decided to stop the study due to adverse events, the drug was discontinued gradually by reducing the dose to 25 mg/day for one week before stopping. Patient outcomes were assessed at baseline and 4, 8, 12, 16, 26, 39, and 52 weeks.
This was a multicenter trial conducted in the oncology clinics of several Australian hospitals.
Patients were undergoing the active treatment phase of care.
The study was a double-blind, placebo-controlled, centrally randomized trial that was stratified for institution, sex, anticipated future cytotoxic treatment, and Performance Score:
Sertraline had no significant effect in improving fatigue compared to placebo. Outcomes were compared on the basis of scores at baseline and four and eight weeks.
Stiff, P.J., Fox-Geiman, M.P., Kiley, K., Rychlik, K., Parthasarathy, M., Fletcher-Gonzalez, D., … Rodriguez, T.E. (2013). Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biology of Blood and Marrow Transplantation, 19(1), 49-55.e1.
To evaluate the safety and efficacy of oral aprepitant in combination with ondansetron and dexamethasone in the prevention of acute and delayed nausea and vomiting compared to ondansetron and dexamethasone alone in patients receiving highly emetogenic preparative regimens before autologous or allogeneic stem cell transplant (SCT).
Patients were stratified by gender and randomized to one of two treatments. The aprepitant group received 125 mg oral aprepitant on day one then 80 mg daily during the preparative regimen + 3 days, 7.5 mg dexamethasone IV, and 8 mg ondansetron by mouth every eight hours daily during preparative regimen + 1 day. The placebo group received an oral placebo daily during the preparative regimen + 3 days, 10 mg IV dexamethasone, and 8 mg oral ondansetron every eight hours daily during the preparative regimen +1 day. Lorazepam was used for breakthrough nausea or vomiting. Prochlorperazine was allowed only for repeated episodes of vomiting (defined as more than four episodes in any 12-hour period). The primary objective was complete response (CR) rate, defined as no emesis with no or mild nausea.
The study was conducted at Loyola University Medical Center Cardinal Bernardin Cancer Center in Maywood, IL.
All patients were in active antitumor treatment.
This study was a single center, comparative (placebo controlled), randomized, double-blind, phase III trial.
Patients rated the number of emetic episodes and nausea severity on a 100-mm visual analog scale (VAS).
Aprepitant in combination with dexamethasone and ondansetron significantly decreased emesis and significant nausea, without an increase in regimen-related toxicities. The regimen did not affect short-term survival and had no significant impact on the use of as-needed antiemetics or overall nausea scores. It did not negatively affect patient outcomes.
Five myeloablative high-dose cyclophosphamide preparative regimens were used. Only two regimens included total body irradiation (TBI), which is thought to cause more nausea.
Similar to standard-dose chemotherapy regimens, aprepitant demonstrated a much higher impact on emesis than it did on nausea. Aprepitant in combination with dexamethasone and ondansetron significantly decreased emesis and significant nausea, without increasing toxicities or affecting short-term survival; the regimen had no significant impact on the use of as-needed antiemetics or overall nausea scores. Findings suggest that aprepitant assisted in control of nausea as well as emesis.
Stevinson, C., Steed, H., Faught, W., Tonkin, K., Vallance, J.K., Ladha, A.B., . . . Courneya, K.S. (2009). Physical activity in ovarian cancer survivors: Associations with fatigue, sleep, and psychosocial functioning. International Journal of Gynecological Cancer, 19, 73–78.
To investigate the associations between physical activity and health-related outcomes in ovarian cancer survivors and examine any dose-response relationship and to investigate associations between physical activity and peripheral neuropathy, depression, anxiety, sleep latency, use of sleep medication, and daytime dysfunction
Participants with confirmed ovarian cancer from 1985–2005 were asked to complete and return a consent form and questionnaire. Non-responders were sent a reminder postcard after two weeks and a second questionnaire after four weeks. The study took place from May 2006–June 2007.
A total of 359 ovarian cancer survivors participated, of whom 31.1% were meeting the public health physical activity guidelines of the Centers for Disease Control and Prevention. Those meeting the guidelines reported significantly lower fatigue than those who did not meet the guidelines. Meeting the guidelines was significantly inversely associated with peripheral neuropathy, depression, anxiety, sleep latency, use of sleep medication, and daytime dysfunction and was positively associated with happiness, sleep quality, and sleep efficiency. No evidence existed of a dose-response relationship beyond meeting or not meeting the guidelines for any variables.
Ovarian cancer survivors who were meeting physical activity guidelines reported more favorable outcomes of fatigue, peripheral neuropathy, sleep, and psychosocial functioning, compared to those who were sedentary or reported low activity.
Results of this population-based study suggest that ovarian cancer survivors may have fewer and less severe symptoms (e.g., fatigue, depression, neuropathy) and more health-related benefits (e.g, better sleep, greater happiness), if they increase physical activity during or after cancer treatment.
Stevinson, C., Lawlor, D. A., & Fox, K. R. (2004). Exercise interventions for cancer patients: systematic review of controlled trials. Cancer Causes and Control, 15, 1035–1056.
Databases searched were MEDLINE, EMBASE, Cochrane Controlled Trials Register, CANCERLIT, CINAHL, PsycINFO, and SPORTDiscus through December 2003.
Thirty-three studies (25 randomized trials and eight nonrandomized studies) reported in 40 articles were included in the review. Data were pooled for 10 trials that assessed physical functioning and 12 trials that assessed fatigue.
Trials were included if they tested interventions involving regular exercise of any type (e.g., aerobic, resistance, and flexibility). Exercise could be the sole intervention or could be combined with other interventions (e.g., diet counseling). Only prospective trials with a control arm were included. Based on an a priori decision, both nonrandomized and randomized trials were included. There were no restrictions on the outcomes assessed in trials. Nineteen studies tested aerobic exercise interventions, of which eight used cycle ergometers and eight used walking programs. Three trials tested resistive exercise, 10 had combined aerobic and resistive programs, and one was based on team sport activities. Most trials compared an exercise intervention with no intervention; six that did not used information training, psychological therapies, stretching, or tai chi as comparison arms.
Trials of single exercise sessions that measured acute effects were excluded, as were trials that only investigated the effects of physiotherapy. Control arms could not comprise an intervention (e.g., usual care), an alternative intervention (e.g., counseling, relaxation), or a different type of exercise (e.g., aerobic versus flexibility exercises). Trials with healthy or historical control groups were excluded.
Exercise interventions lasted for 10 weeks or longer in 17 trials and two weeks or less in four studies. The longest intervention period of any trial was 26 weeks. Trial quality was assessed by recording whether the following features were incorporated in the study design: randomization, allocation concealment, blinding of the main outcome assessment, and intention-to-treat analysis.
Reductions in cancer-related fatigue were reported in 10 studies, although statistical significance was not reached or not tested for in three of them. No differences between groups were reported for fatigue in six trials immediately after the intervention or several months later. Pooling the data from the 12 trials that assessed fatigue suggested that there was no overall effect of exercise on symptoms of fatigue (standardized mean difference [standard deviation (SD)] in fatigue = -0.15 [-0.38, 0.09]). Heterogeneity between studies was not related to randomization, allocation concealment, intention-to-treat analysis, or choice of control. However, the effect appeared to vary by population type. Some evidence existed that no effect was found of exercise on fatigue symptoms in trials that recruited patients with any type of cancer and that those that recruited patients with breast cancer found a modest reduction in symptoms of fatigue among those allocated to exercise (standardized mean difference [SD] = -0.52 [-0.95,-0.09]). There was no strong evidence of small study bias in this meta-analysis by the Beggs and Egger tests.
The authors generally concluded that there were methodologic limitations associated with many of the studies and that these limitations may have contributed to the inconsistencies among the results.
Limitations included
Two studies may have included participants in the control group who had declined to undertake the intervention; in five other studies, it was unclear whether eligibility (including willingness to participate) was determined prior to group allocation or whether the control group may have solely or partly consisted of those who declined to be allocated to exercise.
Sternberg, C. N., Molina, A., North, S., Mainwaring, P., Fizazi, K., Hao, Y., . . . Scher, H. I. (2013). Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of Oncology, 24, 1017–1025.
To evaluate fatigue outcomes in patients who participated in a phase II trial of abiraterone acetate and prednisone versus placebo and prednisone in patients after docetaxel therapy for metastatic castration-resistant prostate cancer.
In the phase III trial, patients were randomized to receive either abiraterone acetate and prednisone or placebo and prednisone; they later were crossed over to the other intervention arm. Abiraterone inhibits synthesis of testosterone and other androgens, leading to suppression of prostate cancer growth. Patient-reported fatigue was evaluated at baseline and on the first day of each treatment cycle until treatment discontinuation. Median treatment durations were eight and four months across study groups, and median duration of follow-up was 20.2 months.
Patients were undergoing multiple phases of care.
This was a randomized, controlled, single-blind, crossover study.
Treatment with abiraterone acetate and prednisone in this group of patients was associated with improvement in fatigue symptoms.
Findings demonstrated that treatment with abiraterone acetate in addition to prednisone was effective in improving fatigue in patients with metastatic castration-resistant prostate cancer. This is an important step forward to manage fatigue in this group of patients. This approach can only be expected to be of benefit for this disease, based on the understood actions of the drug. Nurses can advocate for the use of this approach in patients with severe fatigue.
Stephenson, N.L., Swanson, M., Dalton, J., Keefe, F.J., & Engelke, M. (2007). Partner-delivered reflexology: Effects on cancer pain and anxiety. Oncology Nursing Forum, 34, 127–132.
To test the effectiveness of reflexology delivered by partners in patients with cancer
An initial reflexology session of 30 minutes was provided in the hospital setting. The session included relaxing techniques, 15 minutes of reflexing areas of the feet corresponding to areas of the patient’s reported pain and body parts where cancer or pain was located. The final five minutes were used to reflex the entire area of the feet. Partners were taught how to perform a reflexing protocol and provided with associated written materials. Partners practiced the technique on the investigator or the patient and were given feedback on the technique. Signs and symptoms of deep vein thrombosis were reviewed to alert partners to avoid foot reflexology in that situation. Patients in the control group received usual care plus special attention for 30 minutes, consisting of reading a selection of the patient’s choice to the patient. Study data were obtained pre- and postintervention.
A randomized controlled trial design was used.
In the total sample, there were no significant differences between groups in pain outcome measures. In patients with higher baseline pain levels (≥ 5), significant differences were found in favor of the reflexology group in analysis of variance (p = 0.001, eta2 for effect size = 0.12). Patients in the reflexology group had significant reduction in anxiety, with a 62% reduction from baseline to postintervention in those receiving reflexology versus 23% reduction in controls. Among those with higher levels of anxiety (≥ 5), significant differences were found in favor of reflexology (p = 0.001, eta2 = 0.13).
Partner-delivered reflexology was associated with reduction in pain and anxiety compared to controls. The intervention appeared to be most effective in patients with higher levels of pain and anxiety.
Findings suggest that foot reflexology can be helpful for patients with cancer in reducing anxiety and perception of pain in the short term. Study findings suggest that partners can be taught to provide this type of intervention. Addition of partner-delivered reflexology might be a useful adjunct for anxiety and pain control; however, trained individuals need to be available to provide the teaching or the actual intervention. Involvement of caretakers in patient care with this type of approach might be a useful way to empower patients and caregivers.